Clinical Trials

  • Principal Investigator:

    Jennifer M. Bain, MD, PhD
    A natural history study of hnRNP and other genetic neurodevelopmental disorders.
  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. We are looking for families and/or individuals (affected or unaffected) of any ethnic background with a family history of Alzheimer's disease and willing to participate.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    This is a global, multicenter, placebo-controlled, phase 3 study evaluating the efficacy and safety of riliprubart in adult participants with CIDP who are refractory or had an insufficient response to standard of care (SOC) therapies, defined as Ig administered IV (IVIg) or SC (SCIg), or corticosteroids. Treatment duration will be 48 weeks. Participant must be 18 years old at the time of signing the informed consent.
  • Principal Investigator:

    Matthew B. Harms, MD
    This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS. The ALS...
  • Principal Investigator:

    Scott A. Small, MD
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    Scott A. Small, MD
    For over 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing a...
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Patrick J. Lao, PhD
    The purpose of this study is to determine how inflammation is related to changes in the brain that occur during the progression of Alzheimer's disease. If you are eligible for this study, we will ask you to complete 3-4 study visits over the course of about 5 months. Participation includes memory testing, a blood draw, MRI, PET scans, and a lumbar puncture (spinal tap). You will be compensated $750 plus travel costs. After 2 years, we will invite you to return for a follow-up.
  • Principal Investigator:

    Sloane Heller, MD
    The purpose of this study is to understand how liver disease affects thinking and memory, both before and after transplant. Participants will take a cognitive test, which will be a series of tasks and questions similar to a video game, at home on their own computers, tablets, or phones. This will take approximately 45 minutes, and participants will do this once a year for 3 years. We will assess how thinking and memory changes over time and in response to transplant.
  • Principal Investigator:

    Rebecca Straus Farber, MD
    We need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID-19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID-19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find...

Pages